Filing Flows › Alnylam Pharmaceuticals (ALNY) › Net product revenues revenue
Alnylam Pharmaceuticals (ALNY) Net product revenues revenue by quarter
Alnylam Pharmaceuticals' Net product revenues revenue was $1.3B in Q3 2026 (third quarter 2026), +11% from Q2 2026. Over the last 7 quarters it ranged from $450M (Q4 2024) to $1.3B (Q3 2026).
| Quarter | Net product revenues revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.3B | +11% | +52% |
| Q2 2026 | $1.2B | +18% | +75% |
| Q4 2025 | $995M | +17% | +121% |
| Q3 2025 | $851M | +27% | — |
| Q2 2025 | $672M | +43% | — |
| Q1 2025 | $469M | +4% | — |
| Q4 2024 | $450M | — | — |
Q3 2026 at a glance
Alnylam Pharmaceuticals, Q3 2026: revenue $1.5B (+17% year over year), operating margin 23.7%, net earnings $2.2B, operating cash flow $341M. The chart follows the revenue to costs, profit and cash.
Questions
What is Alnylam Pharmaceuticals' Net product revenues revenue?
Alnylam Pharmaceuticals' Net product revenues revenue was $1.3B in Q3 2026 (third quarter 2026), +11% from Q2 2026.
How has Alnylam Pharmaceuticals' Net product revenues revenue changed?
Over the last 7 quarters it ranged from $450M (Q4 2024) to $1.3B (Q3 2026).
Q3 2026 results → · How Alnylam Pharmaceuticals makes money →